Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Glioblastoma Multiforme
- Study the safety and effectiveness of antineoplastons A10 and AS2-1 in patients with
incurable glioblastoma multiforme.
- Describe response, tolerance to, and side effects of this regimen in these patients.
OUTLINE: Patients receive gradually escalating doses of intravenous antineoplaston A10 and
antineoplaston AS2-1 six times a day until the maximum tolerated dose is reached. Patients
achieving complete response (CR) continue treatment for an additional 8 months after
reaching CR. Treatment continues for at least 3 months in the absence of unacceptable
toxicity or disease progression.
Tumors are measured every 2 months during the first year and every 3 months during the
PROJECTED ACCRUAL: Approximately 20-40 patients will be accrued in this study.
Primary Purpose: Treatment
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
United States: Federal Government
|Burzynski Research Institute||Houston, Texas 77055-6330|